June 5, 2008-The European Medicines Agency (EMEA) has recommended the immediate implementation of changes to the product information for neupro (rotigotine), from Schwarz Pharma Ltd, stating that it must be stored in a refrigerator (at a temperature of between 2ºc and 8ºc). The new storage conditions are intended to reduce the possible occurrence of crystallisation of the active substance which has been reported in patches of Neupro.
Neupro is a centrally-authorised medicine used for the treatment of Parkinson’s disease. Its active substance, rotigotine, is a dopamine agonist. Neupro is the only medicine for Parkinson’s disease that is administered as a transdermal patch.
The whole story can be read here.
No comments:
Post a Comment